SMART stent shows 75% superficial femoral patency at 2 years


AT ISET 2013

MIAMI BEACH – At 2-year follow-up, the SMART stent was associated with a 75% primary patency rate in patients with obstructive superficial femoral artery disease.

The findings were noted in the STROLL study (SMART Vascular Stent Systems in the Treatment of Obstructive Superficial Femoral Artery Disease). The primary patency rate was 82% at 12 months and 75% at 24 months in 250 patients aged 30 years and older who were enrolled in the single-arm, multicenter study, Dr. William Gray reported at the International Symposium on Endovascular Therapy 2013.

Dr. William A. Gray

At 12 months, 87% were free from target lesion revascularization; at 24 months, 80% were free from target lesion revascularization, said Dr. Gray, director of endovascular services at Columbia University Medical Center, New York.

No major adverse events were noted at 30 days after the index procedure, and the rate of stent fractures was 2% at 12 months, with no additional stent fractures occurring between 12 and 24 months.

All stent fractures were type 1, with no incidents of type II-V fractures, he reported.

Additionally, more than 80% of patients had improvement or normalization of peripheral artery disease outcomes as measured using Rutherford-Becker classification and ankle brachial index, he noted.

Study participants had de novo or restenotic native superficial femoral artery lesions or total occlusions of 4-15 cm (mean, 77 mm) in length, and reference vessel diameters of 4.0-6.0 mm. Nearly 24% had total occlusions, and 47% had diabetes.

All were treated using the SMART Control nitinol self-expanding stent system manufactured by Cordis. SMART stents have been approved for peripheral indication in international markets since 1999. In 2012, the SMART Control nitinol stent system, which was previously approved for use in the iliac arteries, was also approved by the U.S. Food and Drug Administration for use in the superficial femoral artery and/or the proximal popliteal artery.

The findings "speak well of the efficacy of the SMART stent," Dr. Gray said. Follow-up will continue until 3 years post procedure.

The STROLL study was sponsored by Cordis. Dr. Gray was a principal investigator for the study and serves as a paid advisory board member and consultant for Cordis.

Recommended Reading

Progress, obstacles cited in building STEMI networks
MDedge Cardiology
Is same-day discharge after PCI safe?
MDedge Cardiology
STREAM trial endorses fibrinolysis-first in selected STEMIs
MDedge Cardiology
U.S. post-PCI cardiac rehabilitation referrals lag
MDedge Cardiology
Mortality after surgery for radiation-related cardiac problems unexpectedly high
MDedge Cardiology
Strokes pop up post aortic valve surgery
MDedge Cardiology
Women have more complications with ICDs
MDedge Cardiology
Vascular surgeons get superior outcomes in aortic aneurysm repair
MDedge Cardiology
Rheolytic thrombectomy plus adjunctive therapy speeds DVT treatment
MDedge Cardiology
High patency seen for interwoven nitinol stents in femoropopliteal lesions
MDedge Cardiology